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BACKGROUND:We conducted a baseline prevalence survey of unvaccinated 11- to 18-year olds to inform effectiveness studies for the
new human papillomavirus (HPV) immunisation programme in Scotland.
METHODS: Participants were recruited from schools and colleges and invited to provide demographic data and an anonymous urine
sample for type-specific HPV testing.
RESULTS: Among females aged 11–14 years, the weighted prevalence was 1.1% overall; 0.9% for high-risk types and no infections were
associated with types 16 and 18. Among 15- to 18-year old females, the weighted prevalence was 15.2% overall; 12.6% for high-risk
types and 6.5% for types 16 and 18. Among females aged 16–18 years, infection was more frequently associated with attending
college and rural schools, and showed a trend towards increasing prevalence with increasing social deprivation (P¼0.045).
Among males aged 11–14 years, the weighted prevalence was 1.4% overall; 1.0% for high-risk types and 0.7% for types 16 and 18.
Among 15- to 18-year old males, the weighted prevalence was 3.9% overall; 2.4% for high-risk types and 0.7% for types 16 and 18.
CONCLUSIONS: Human Papillomavirus prevalence is low among 11- to 14-year olds, which includes the age group targeted for routine
vaccination. The prevalence in males and correlation with deprivation require further investigation.
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Persistent infection with high-risk types of human papillomavirus
(HPV) is recognised as the principal cause of cervical cancer, the
second most common cancer among women globally (Clifford
et al, 2006). Vaccines that protect against HPV-16 and -18, the
types implicated in over 70% of cervical cancers, have recently
been developed (Clifford et al, 2006). As these vaccines are
incorporated into routine immunisation programmes, it will be
necessary to monitor their impact and effectiveness through
routine surveillance of vaccinated cohorts. Suitable surveillance
end points include changes to the incidence and prevalence of
both HPV-related cervical disease (abnormal cervical smears, pre-
cancerous lesions and invasive cancers) and type-specific HPV
prevalence (European Centre for Disease Prevention and Control,
2007). Currently, in the United Kingdom, HPV infection is not
routinely diagnosed in the clinical setting, as it is largely
asymptomatic and no treatment is available. Consequently
routinely collected prevalence data are usually unavailable. In
particular, there is a paucity of data on the prevalence of infection
among the age groups targeted for vaccination.
In Scotland, the bivalent HPV vaccine, which protects against
the high-risk HPV types 16 and 18, was introduced into the
national immunisation schedule in September 2008, targeting
females aged 12–13 years. To facilitate the ongoing monitoring of
HPV infection in vaccinated cohorts, before the introduction of the
immunisation programme, we undertook a comparative baseline
cross-sectional survey of unvaccinated Scottish adolescents to
measure the type-specific prevalence of HPV infection and its
association with age, sex and social deprivation. We report here
the findings of this survey, which we believe is the first population-
based prevalence survey of HPV infection among adolescent males
and females in the United Kingdom and one of only a few surveys
(Andersson-Ellstrom et al, 1996; De Sanjose et al, 2003; Dunne
et al, 2007) that have included younger adolescents in the age
group targeted for vaccination.
MATERIALS AND METHODS
Study design and recruitment of subjects
This study was funded by the Scottish Government and received
approval from the South Glasgow and Clyde Research Ethics
Committee. Between January and May 2008, we recruited males
and females (11–18 years) attending publicly funded (state)
and private fee-paying (independent) schools. Approximately 35%
of young people in Scotland leave school by the age of 16 years
(HM Inspectorate of Education, 2006), and leaving school early
is correlated with social deprivation. Although we did not
specifically sample early school leavers, in order to increase the
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recruitment of those who left school early to attend colleges of
further education (hereafter known as colleges).
We sampled education authorities (EAs) using population
proportional to size and, within them, we invited all state and
independent schools and colleges to participate. The target sample
was stratified by age, with oversampling in older age groups. We
aimed to recruit a sample size that would provide sufficient power
to estimate the overall prevalence of HPV infection, the prevalence
by age, sex and social deprivation and the specific genotypes in
circulation. For state schools, we collected data on the denomina-
tional (religious) affiliation of the school and whether it was in an
urban or rural setting. The achieved sample had a precision of
±3% on the estimated prevalence of HPV and a power of 80% to
detect differences in prevalence of at least 8% between the two
subgroups with 1000 participants.
Participants gave written informed consent, as did the parents of
students aged o16 years. All the students within a selected year were
invited to a presentation given by the study team, in which they were
asked to take part in the study by providing an anonymous specimen
of urine for HPV testing along with information on their age, sex and
postal code using a standardised data-collection form. College
students were recruited directly on campus on the designated study
days. Samples and data forms were labelled and linked with a unique
anonymous study number. Participants were not given their results.
A urine sample was chosen, as it is a non-invasive method to access
the population of interest.
Laboratory analysis
As urine contains relatively few cells, an HPV assay (HPV Inno-LiPA
HPV Genotyping Extra assay, Innogenetics, Gent, Belgium) with a
high analytical sensitivity was used (Appendix 1). This assay was
previously validated in urine, inc o m p a r i s o nt oag o l ds t a n d a r d
sample (cervical liquid-based cytology sample or penile swab), by
m e a s u r i n gt h eH P Vc o n c o r d a n c eb ys a m p l et y p e( C u s c h i e r iet al,
2008). Briefly, samples were collected from females and males aged
o25 years attending a drop-in clinic for integrated sexual health
services. The sensitivity of the assay for detection of all HPV types
was 90.5% (95% confidence interval (95% CI): 79.3–96.9) for females
and 55.9% (95% CI: 37.8–72.8) for males, and the specificity was 71%
(95% CI: 61.0–79.5) for females and 63.2% (95% CI: 54.2–71.4) for
males. Discrepancy analysis indicated that the distribution of HPV
types in urine was similar to that observed in the gold standard
sample for both males and females.
Data analyses
Data were entered into a Microsoft Access database. Postal codes
were automatically assigned a point on the Scottish Index of
Multiple Deprivation (SIMD) (Scottish Government, 2009) at data
entry and then destroyed to preserve individual anonymity.
Scottish Index of Multiple Deprivation was grouped into ordinal
quintiles of deprivation. Age was grouped into two-year categories
(11–12 up to 17–18) corresponding approximately to school
years. For individuals missing age data, we imputed a value based
on their school year.
Data were analysed using Intercooled STATA version 9.2
(STATA Corp Ltd, College Station, TX, USA) and R version 2.9.0
(R project for statistical computing, open-source, free software).
The institutional and student response rates by type of educational
establishment were determined and the characteristics of the
sample described. A comparison was made between the character-
istics of the total sample and the 1866 samples included in the final
analysis using Fisher’s exact and w
2-tests. Prevalence estimates and
95% CIs were calculated. A crude and weighted stratified analysis
of HPV prevalence by sex was conducted using the survey package
in R, with schools nested within EAs. Sample weights were
calculated to account for the sampling proportional to size of the
EA and response bias. We compared the prevalence of HPV in
11- to 14-year olds (which includes those aged 12–13 years, the
target of the primary vaccination programme) with the prevalence
in 15- to 18-year olds (which includes those targeted as part of the
catch-up immunisation campaign). The percentage of infections
and 95% CIs due to infections with the bivalent vaccine types 16
and 18, with high-risk types and with multiple types were
calculated as ratio estimates for females aged 15–18 years.
Weighted odds ratios (OR) for HPV infection were calculated
using logistic regression accounting for the survey design. Two
separate regressions were carried out, one restricted to females
attending schools and another on all females aged 16–18 years
(including those attending college), as there is confounding
between age, attending a college and deprivation. No regression
analysis was carried out using the data for males and females
together, as the data for males were inconsistent and did not
exhibit the same trends. All estimates were weighted to account for
the age-stratified sampling strategy and to adjust for the lower
response rate associated with high deprivation. Weights were
calculated on the basis of the mid-year population estimates for
Scotland (General Register Office for Scotland, 2008). Only those
who provided an adequate sample for HPV detection were
included in the final analyses.
RESULTS
Response to the study
Of the 32 EAs in Scotland, 8 were invited and all agreed to
participate in the study; 51% (58/114) of state schools, 75% (3/4) of
independent schools and 60% (9/15) of colleges agreed to take
part. Within schools, the response rate, calculated on the basis of
the number of registered students in a year and not on the number
who actually attended the study presentation, was estimated at
15% (2219/14417) overall. The response rate was 14% (1980/
13713) for state schools (range, 0.3–45% per individual school)
and 34% (239/704) for independent schools (range, 18–39%). The
response rate at colleges was not recorded, as reliable denominator
data was not available.
Sample characteristics
Excluding leaking samples and those with insufficient volume,
2447 (95%) of 2575 submitted samples were suitable for
processing; 1866 (72%) contained amplifiable DNA and were
classified as valid for HPV detection. Submission of an invalid
sample was not related to age, deprivation, recruitment from an
urban or rural setting or attending a denominational school
(Table 1). Of the invalid samples (without amplifiable DNA), 75%
came from males; males were twice as likely as females to submit
invalid samples. Following the exclusion of these samples, the
proportion of males in our sample decreased from 47 to 39%, and
was significantly lower than that for females (Po0.001).
In the general Scottish population of 11- to 18-year olds, B21%
are from areas of high deprivation (most deprived quintile;
General Register Office for Scotland, 2008); 15% (280) of the 1866
participants in the final analysis came from areas of high
deprivation (Table 1). A total of 10% (189) were aged 11–12
years; 17% (309) 13–14 years; 42% (774) 15–16 years and 32%
(594) 17–18 years. In total, 9% (174) attended independent schools
(compared with B5.5% of the Scottish secondary school popula-
tion (HM Inspectorate of Education, 2006)) and 12% (228)
attended colleges. In Scotland, B55% of 17-year olds are still in
school (HM Inspectorate of Education, 2006), compared with 72%
of our sample of 17- to 18-year olds. Approximately 11% (213) of
respondents attended denominational schools, compared with 17%
nationally (HM Inspectorate of Education, 2006).
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Among females aged 11–14 years (Table 2), the weighted prevalence
of HPV was 1.1% (95% CI: 0.0–2.8). No 11- to 14-year-old females
were infected with the bivalent vaccine types 16 and 18. The weighted
prevalence of HPV-6 and -11 was 0.1% (95% CI: 0.0–0.4).
The weighted prevalence of high-risk infections (infections with types
16, 18, 26, 31, 33, 35, 39, 51, 53, 56, 58, 59, 66, 68, 69, 70, 73 and 82) was
0.9% (95% CI: 0.0–2.6). None had multiple infections.
Among the 15- to 18-year olds, the weighted prevalence was
15.2% (95% CI: 10.8–19.7); 42.5% (95% CI: 32.7–52.2) of all
infections were with types 16 and 18 (weighted prevalence¼6.5%;
95% CI: 4.3–8.6). The weighted prevalence of HPV-6 and -11 was
2.9% (95% CI: 0.7–5.1). High-risk infections accounted for 82.7%
(95% CI: 76.0–89.3) of all infections (weighted prevalence¼12.6%;
95% CI: 9.3–15.9); 50.3% (95% CI: 40.9–59.6) had multiple
infections (weighted prevalence¼7.7%; 95% CI: 4.6–10.7). Human
papillomavirus 16 was most prevalent (weighted prevalence¼
3.9%; 95% CI: 2.2–5.7; Figure 1), followed by HPV-18 (weighted
prevalence¼3.2%; 95% CI: 1.5–5.0), HPV-51 (weighted pre-
valence¼3.0%; 95% CI: 1.5–4.6), HPV-31 (weighted prevalence¼
2.3%; 95% CI: 0.7–3.9) and HPV-6 (weighted prevalence¼2.2%;
95% CI: 0.0–4.4).
Independent risk factors for HPV infection
Among females attending school (Table 3), age was a statistically
significant predictor of HPV positivity (P-trend¼0.004), with a
much higher prevalence among those aged 17–18 years.
There was a trend (P¼0.017) towards higher positivity with
deprivation, although this trend was not strictly linear. In compa-
rison to females in the most affluent quintile, those in the medium
quintile of deprivation had a greater OR of being HPV positive
(OR¼2.4; 95% CI: 0.9–6.5) than those in the second most
deprived quintile (OR¼1.4; 95% CI: 0.7–2.6). Overall, compared
with those in the most affluent quintile, the OR of being HPV
positive was greatest among those in the most deprived quintile
(OR¼3.4; 95% CI: 1.0–12.0).
There was no evidence that HPV positivity varied according to
state versus independent school, school denomination or urban
versus rural setting of the school.
Among females aged 16–18 years, those aged 17–18 years had
increased odds of being positive (of 1.9; 95% CI: 1.0–3.6)
compared with those aged 16 years. There was also a statistically
significant trend (P-trend¼0.045) towards increased risk of
infection with increasing deprivation. Again this trend was not
linear, as the risk of infection was highest in those from the second
most deprived quintile (OR¼3.0; 95% CI: 1.3–7.1) rather than in
those from the most deprived quintile (OR¼2.1; 95% CI: 0.7–6.5).
A sizeable proportion of 16- to 18-year olds (21% of the sample)
attend colleges. We observed an association between HPV
infection and attending a college rather than an urban school
(OR¼5.4; 95% CI: 3.5–8.4). All colleges are in urban areas.
Adjusting for deprivation, females attending rural schools were
Table 2 Weighted HPV prevalence among male and female students aged 11–14 and 15–18 years in Scotland in 2008 (n¼1866)
HPV type
Females aged 11–14
years, % (95% CI)
Females aged 15–18
years, % (95% CI)
Males aged 11–14
years, % (95% CI)
Male aged 15–18
years, % (95% CI)
All-types 1.1 (0–2.8) 15.2 (10.8–19.7) 1.4 (0.0–2.9) 3.9 (1.3–6.6)
HPV-16 and -18 (bivalent vaccine types) 0.0 (0.0–0.0) 6.5 (4.3–8.6) 0.7 (0.0–1.5) 0.7 (0.0–1.5)
Non-vaccine types (types other than 16 and 18) 1.1 (0–2.8) 8.8 (5.5–12.0) 0.7 (0.0–1.6) 3.2 (0.9–5.6)
Non-vaccine types 6 and 11 0.1 (0–0.4) 2.9 (0.7–5.1) 0.7 (0.0–1.8) 0.9 (0.0–1.9)
High-risk types (single or multiple infections±low-risk types)
a 0.9 (0–2.6) 12.6 (9.3–15.9) 1.0 (0.0–2.1) 2.4 (0.0–4.7)
Low-risk types only (multiple and single infections)
b 0.1 (0–0.4) 2.6 (1.1–4.2) 0.4 (0.0–1.0) 1.6 (0.0–3.4)
Multiple infections 0.0 (0.0–0.0) 7.7 (4.6–10.7) 0.3 (0.0–0.9) 1.2 (0.0–2.4)
HPV infections
Single type 1.1 (0.0–2.8) 7.6 (5.4–9.8) 1.1 (0.0–2.3) 2.8 (0.6–5.0)
Two types 0.0 (0.0–0.0) 4.3 (1.5–7) 0.0 (0.0–0.0) 0.8 (0.0–1.9)
Three types 0.0 (0.0–0.0) 2.6 (1.2–4.0) 0.3 (0.0–0.9) 0.2 (0.0–0.6)
Four types or more 0.0 (0.0–0.0) 0.8 (0.0–1.6) 0.0 (0.0–0.0) 0.2 (0.0–0.4)
Abbreviation: HPV¼human papillomavirus.
aHigh-risk types include types 16, 18, 26, 31, 33, 35, 39, 51, 53, 56, 58, 59, 66, 68, 69, 70, 73 and 82.
bLow-risk types include types 6,
11, 40, 43, 44, 54 and 71.
Table 1 Characteristics of respondents to a survey of HPV infection
among students in schools and colleges in Scotland from January to
May 2008
All respondents
(N¼2575),
%( n)
Respondents submitting
valid samples
(N¼1866), % (n) P-value
Sex
Male 46.2 (1190) 38.8 (724) Po0.001
Female 52.1 (1341) 60.1 (1121)
Not reported 1.7 (44) 1.1 (21)
Age group (years)
11–12 10.7 (276) 10.1 (189) P¼0.459
13–14 16.5 (424) 16.6 (309)
15–16 39.2 (1009) 41.5 (774)
17–18 33.6 (866) 31.8 (594)
Deprivation category
a
Low 24.0 (619) 23.8 (444) P¼0.772
Medium–low 21.4 (551) 21.2 (396)
Medium 17.7 (457) 17.6 (329)
High–medium 17.7 (457) 17.8 (333)
High 14.8 (381) 15.0 (280)
Not reported 4.3 (110) 3.4 (63)
Type of educational institute
Independent
school
8.5 (209) 9.3 (174) P¼0.005
State school 78.3 (1915) 78.5 (1464)
College 13.2 (323) 12.2 (228)
Denominational school
No 89.2 (2297) 88.6 (1653) P¼0.197
Yes 10.8 (278) 11.4 (213)
Setting
Rural 27.7 (714) 28.4 (530) P¼0.636
Urban 72.3 (1860) 71.6 (1336)
Abbreviation: HPV¼human papillomavirus.
aDeprivation category is derived from
Scottish Index of Multiple Deprivation.
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(OR¼2.2; 95% CI: 1.4–3.6). Again, denominational affiliation of
the school had no association with HPV status.
HPV prevalence among males
Among males aged 11–14 years (Table 2), the weighted prevalence
of HPV was 1.4% (95% CI: 0.0–2.9). The weighted prevalence
of types 16 and 18 was 0.7% (95% CI: 0.0–1.5). The weighted
prevalence of HPV-6 and -11 was 0.7% (95% CI: 0.0–1.8).
The weighted prevalence of high-risk infections was 1.0% (95%
CI: 0.0–2.1) and of multiple infections was 0.3% (95% CI: 0.0–0.9).
Among males aged 15–18 years, the weighted prevalence was
3.9% (95% CI: 1.3–6.6). The weighted prevalence of types 16 and
18 was 0.7% (95% CI: 0.0–1.5). The weighted prevalence of HPV-6
and -11 was 0.9% (95% CI: 0.0–1.9). The weighted prevalence of
high-risk infections was 2.4% (95% CI: 0.0–4.7) and of multiple
infections was 1.2% (95% CI: 0.0–2.4). Human papillomavirus 70
was most prevalent (weighted prevalence¼0.9%; 95% CI: 0.0–2.2;
Figure 1), followed by HPV-6 (weighted prevalence¼0.8%; 95%
CI: 0.0–1.9), HPV-16 (weighted prevalence¼0.5%; 95% CI:
0.0–1.1) and HPV-51 (weighted prevalence¼0.5%; 95% CI: 0.0–1.5).
DISCUSSION
This study provides information on the overall and type-specific
prevalence of HPV infection by age, sex and social deprivation,
and on the distribution of vaccine and non-vaccine types and high-
and low-risk types in a sample of the general unvaccinated
adolescent population. Few direct population-based studies of
HPV have been conducted, few have recruited participants in the
age range targeted for vaccination (p13 years) and few have
included males.
Female prevalence
In our sample of 11- to 14-year olds, the overall weighted
prevalence of HPV was low (1%); no infections were associated
with the bivalent vaccine types 16 and 18, although one infection
with HPV type 6 (which can be prevented by the quadrivalent
vaccine) was detected. In this age group, most of those who were
infected were infected with a high-risk type. Among females aged
15–18 years, the overall weighted prevalence of HPV was
substantially higher (15%); over 80% were infected with high-risk
types and almost half of all infections were with types 16 and 18.
There is some variation in the HPV prevalence estimates
reported in surveys of the general population of adolescent
women, and as most of these have used cervical swabs or brush
samples, which have a higher sensitivity than urine, a direct
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Figure 1 Type-specific prevalence of HPV infection among (A) female
and (B) male students aged 15–18 years in Scotland in 2008.
Table 3 Factors associated with HPV infection among (model A)
females attending secondary schools and (model B) all 16- to 18-year-old
females in Scotland in 2008
Variable % (95% CI)
Odds ratio
(95% CI) P-value
Model A: females in school
Age group (years)
11–12 0.4 (0.0–1.3) 0.1 (0.0–0.8) 0.004
a
13–14 1.4 (0.0–4.1) 0.2 (0.0–1.8)
15–16 (ref) 6.9 (3.8–10.0) 1
17–18 15.8 (11.1–20.4) 2.5 (1.4–4.5)
Deprivation category
Low (ref) 3.4 (1.4–5.5) 1
Medium–low 3.6 (1.3–6.0) 1.0 (0.4–2.6) 0.017
a
Medium 9.2 (2.8–15.7) 2.4 (0.9–6.5)
High–medium 4.5 (1.8–7.2) 1.4 (0.7–2.6)
High 7.7 (0.0–16.5) 3.4 (1.0–12.0)
Type of educational institute
Independent school (ref) 2.5 (0.0–5.7) 1 0.829
State school 5.9 (3.5–8.3) 1.2 (0.3–4.6)
Denominational school
No (ref) 5.5 (3.1–7.8) 1 0.312
Yes 6.9 (0.0–14.4) 0.6 (0.2–1.7)
Setting
Rural (ref) 5.7 (1.6–9.7) 1 0.734
Urban 5.5 (3.0–8.1) 0.9 (0.4–1.9)
Model B: females aged 16–18 years
Age group
16 (ref) 11.1 (4.0–18.2) 1 0.071
17–18 24.2 (16.9–31.5) 1.9 (1.0–3.6)
Deprivation Category
Low (ref) 9.9 (4.3–15.6) 1 0.045
a
Medium–low 9.9 (2.7–17.1) 0.9 (0.3–2.8)
Medium 17.9 (9.2–26.6) 1.6 (0.8–3.3)
High–medium 27.7 (14.2–41.3) 3.0 (1.3–7.1)
High 24.9 (12.0–37.8) 2.1 (0.7–6.5)
Type of educational institute
Urban school (ref) 9.2 (5.0–13.5) 1 o0.001
Rural school 14.4 (8.6–20.2) 2.2 (1.4–3.6)
Urban college 38.3 (31.1–45.5) 5.4 (3.5–8.4)
Denominational school
No (ref) 19.8 (13.8–25.7) 1 0.700
Yes 13.0 (0.0–25.9) 1.2 (0.5–2.9)
Abbreviations: HPV¼human papillomavirus; ref¼reference value.
aP-value for trend.
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15- to 17-year-old female secondary school students in Sweden
(Andersson-Ellstrom et al, 1996) reported a similar HPV
prevalence rate of 12%, and, although a survey of 14- to 19-year-
old females in the United States (Dunne et al, 2007) reported a
higher prevalence rate of 25%, we detected a similar prevalence of
24% among our 17- to 18-year-old respondents. The prevalence
rate among the 17- to 18-year-old women in our study is also
comparable with that reported among 15- to 19-year olds attending
cervical screening in England (Peto et al, 2004). To our knowledge,
only a couple of other surveys have used urine as a sample for HPV
detection; these have targeted older women (aged 18–25 years)
who were selected on the basis of either being sexually
inexperienced (prevalence rate¼6%; Prustya et al, 2005) or
sexually active (prevalence rate¼27%; Manhart et al, 2006),
making a direct comparison with our results inappropriate.
In our sample, increasing age, and among the older age
groups, increasing deprivation, attending college and attending a
rural school were associated with HPV infection. The association
between HPV infection and deprivation was not absolute, as the
risk of infection did not increase in a completely linear manner
with deprivation. Overall though, those in more deprived areas
were more at risk of infection than those in the most affluent
areas. Attending a college was more strongly associated with
HPV infection than social deprivation; in our sample, 40% of
those attending college resided in the most deprived areas
(highest quintile of deprivation, as defined by the SIMD). This is
important because it is recognised that those from deprived
areas are less likely to attend cervical screening (NHS Greater
Glasgow and Clyde, 2006) and more likely to develop cervical
cancer (NHS Information Services Division, 2007).
Male prevalence
The HPV prevalence rates detected for males in both age
groups was low and is lower than rates reported in most
other studies (Dunne et al, 2006). Among males, the prevalence
of HPV was almost threefold lower among 11- to 14-year olds
compared with 15- to 18-year olds. The prevalence of vaccine
types was the same, and a similar prevalence of HPV types 6 and
11 (the most common types associated with genital warts)
were observed.
Males aged 11–14 years had a similar prevalence of HPV
compared with females of the same age, although the prevalence
of types 16, 18, 6 and 11 was higher. Conversely, males aged
15–18 years had an almost fourfold lower prevalence than that
reported among females of the same age. The difference in
prevalence by sex in this older age group may be explained by a
number of factors, in particular, by the much lower sensitivity of
the urine assay in males and by the shorter duration of infection in
males (Giuliano et al, 2008) compared with females (Ho et al,
1998; Woodman et al, 2001; Richardson et al, 2003). Males aged
14–19 years have been reported to have a seroprevalence of over
ninefold lower than females of the same age (Dunne et al, 2009).
Adolescent males also tend to have younger female partners who
may have lower rates of infection. A similar age-related
discrepancy in rates of Chlamydia infection has previously been
reported (Fenton et al, 2001).
The pattern of HPV infection among the general population
of young adolescent males requires further investigation. Addi-
tional research is warranted to quantify the impact of female
vaccination on herd immunity in males, although a reduction in
the incidence of genital warts in heterosexual males of an age
similar to that of vaccinated females has already been demon-
strated (Fairley et al, 2009). This information will allow the cost
effectiveness of HPV immunisation programmes to be quantified
more accurately.
Limitations
Our study was subject to a number of limitations, which are likely
to have resulted in an underestimation of HPV prevalence in the
study population.
We used urine as a sample for HPV detection in this survey. The
sensitivity and specificity of urine for HPV detection is lower than
other sample types such as genital swabs. The lower sensitivity
(55.9%) and specificity (63.2%) of the assay in male samples
compared with female samples (90.5 and 71%, respectively), as
determined from the assay validation study, would have led to the
systematic underdetection of HPV infection among males. In
addition, samples from males in our study were twice as likely as
samples from females to contain no amplifiable DNA, as
determined by the absence of the cellular housekeeping gene,
and therefore to be invalid for HPV detection. Given this, it is
likely that we have underestimated the prevalence of HPV,
particularly in our sample of males, although we expect the
distribution of HPV types to be accurate, as the assay validation
study demonstrated a similar distribution of HPV types in urine
compared with gold standard specimens.
Those assumed to be most at risk of HPV infection were
underrepresented in our sample because of the lower response rate
from those from areas of high social deprivation, in
which indicators of sexual health are known to be poorer (Scottish
Executive, 2006), and also because the study design excluded those
11- to 18-year olds who were no longer in education and training.
We estimated the response rate to the study (based on the number
of registered students in the school years and not on the number of
students who actually attended the study presentations) to be B14%.
Although this is likely to be an underestimate, the overall response
was still low. This was, in part, due to the low acceptability of
donating a urine sample in this population. Similar problems have
previously been encountered by other population-based surveys of
HPV, particularly those employing genital swabs, with response rates
as low as 4% being reported in recent literature (Partridge et al, 2007).
CONCLUSION
HPV prevalence is low in the 11–14 year age group, which includes
the age group targeted for routine vaccination and so supports
previous evidence used to recommend the optimum age to offer the
vaccine. The relationship between deprivation and HPV prevalence
requires further investigation, especially in relation to the need to
ensure a high uptake of HPV immunisation among those who are less
likely to attend cervical screening. The picture of HPV infection
among males is unclear and requires further investigation.
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Appendix 1
Laboratory analysis
Specimen transit, processing and extraction Urine was trans-
ported to the laboratory and refrigerated, ideally within 24h of
collection, at 41C, for a maximum of 7 days, then stored at  701C.
Urine samples were thawed in batches, a 5-ml aliquot was removed
and centrifuged at 2800r.p.m. for 20min and the supernatant was
discarded; 3ml of sterile phosphate-buffered saline (PBS) was
added to the pellet, vortexed until fully re-suspended, centrifuged
for a further 20min at 800g, the supernatant discarded and 1ml of
PBS added. Washed urine suspensions were frozen at  701C,
pending nucleic acid extraction. The 1ml washed urine suspen-
sions were extracted on an MDX (Qiagen Ltd., Crawley, UK)
platform using the Qiagen Media Kit according to manufacturer’s
instructions (Qiagen, Crawley, UK). This method uses B300ml for
sample input and elutes nucleic acid in B100ml.
HPV genotyping HPV detection was performed using the HPV
Inno-LiPA HPV Genotyping Extra assay (Innogenetics). This
method involves the PCR amplification of a 65-bp region of HPV
L1 DNA and can resolve 27 different HPV types; 20 high-risk types
(including the 15 types classified as high-risk according to the
International Agency on Research on Cancer); and 7 low-risk types
(including HPV-6 and -11). The assay also incorporates a control
for human DNA in order to ascertain specimen quality/cellularity
and exclude ‘false-negative’ samples. All molecular work was
carried out within a purpose-built, zoned molecular suite and a
positive and negative control was included for every 18 samples
tested.
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